For example, in patients with cardiac conditions, previous exposure to anthracyclines and those who are at high risk for breast cancer recurrence, a doublet platinum taxane chemotherapy has shown similar outcomes to those of anthracycline-taxane in the treatment of TNBC- and HER2-positive diseases [27,28,29]. This evidence concerns the gene ERBB2 and breast carcinoma.